Content about Atorvastatin

March 14, 2013

Wegmans will be offering the popular cholesterol-lowering drug atorvastatin free of charge through the end of the year, according to a report published by the Philadelphia Inquirer.

PHILADELPHIA — Wegmans will be offering the popular cholesterol-lowering drug atorvastatin free of charge through the end of the year, according to a report published by the Philadelphia Inquirer Wednesday. 

February 26, 2013

Greenstone has launched an authorized generic version of a drug used to treat cholesterol.

PEAPACK, N.J. — Greenstone has launched an authorized generic version of a drug used to treat cholesterol.

Greenstone, the generics arm of Pfizer, announced the launch of authorized generic atorvastatin calcium tablets in the 10 mg, 20 mg, 40 mg and 80 mg strengths, in bottle sizes ranging from 90 to 1,000. The drug is a version of the parent company's cholesterol drug Lipitor.

An authorized generic is a brand marketed under its generic name at a reduced price.

November 27, 2012

Ranbaxy Labs has recalled more than three dozen lots of its generic version of a cholesterol-lowering statin drug due to the possible presence of foreign particles, the company said.

NEW YORK — Ranbaxy Labs has recalled more than three dozen lots of its generic version of a cholesterol-lowering statin drug due to the possible presence of foreign particles, the company said.

September 4, 2012

In what could symbolize the so-called "patent cliff" that an executive from healthcare market research firm IMS Health spoke of at a recent trade show, a regional mass merchandise chain is taking what used to be the world's top-selling drug and giving it away for free.

GRAND RAPIDS, Mich. — In what could symbolize the so-called "patent cliff" that an executive from healthcare market research firm IMS Health spoke of at a recent trade show, a regional mass merchandise chain is taking what used to be the world's top-selling drug and giving it away for free.

August 3, 2012

Astrologers would say this is the Age of Pisces, while the Chinese zodiac calls it the Year of the Dragon. For health care, it might be a good time to start calling it the "Great Generic Epoch."

WHAT IT MEANS AND WHY IT'S IMPORTANT — Astrologers would say this is the Age of Pisces, while the Chinese zodiac calls it the Year of the Dragon. For health care, it might be a good time to start calling it the "Great Generic Epoch."

The trend seen in the Generic Drug Savings study, in which generic drugs count for an overwhelming majority of prescriptions written but only about one-quarter of drug spending, has been happening for some time now. But it's also accelerating, and that means a lot for drug makers and policy-makers alike.

July 18, 2012

Dr. Reddy's Labs has launched a generic version of a popular cholesterol drug.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic version of a popular cholesterol drug.

The company announced Wednesday the launch of atorvastatin calcium tablets in the 10-mg, 20-mg, 40-mg and 80-mg strengths.

The drug is a generic version of Pfizer's Lipitor, which had sales of slightly more than $8 billion during the 12-month period ended in March, according to IMS Health.

May 29, 2012

Mylan on Tuesday announced that its subsidiary has received final approval from the Food and Drug Administration for its abbreviated new drug application for atorvastatin calcium tablets, a generic version of Pfizer's Lipitor.

PITTSBURGH — Mylan on Tuesday announced that its subsidiary has received final approval from the Food and Drug Administration for its abbreviated new drug application for atorvastatin calcium tablets, a generic version of Pfizer's Lipitor.

The drug maker said Mylan Labs (formerly Matrix Labs) received the go-ahead to market the drug in the 10-mg, 20-mg, 40-mg and 80-mg strengths. Lipitor had U.S. sales of $8.1 billion for the 12 months ended in March, according to IMS Health.

May 23, 2012

Pfizer has partnered with EatingWell magazine to launch the drug maker's Lipitor For You "Recipes 2 Go" mobile application.

NEW YORK — Pfizer has partnered with EatingWell magazine to launch the drug maker's Lipitor For You "Recipes 2 Go" mobile application.

May 17, 2012

The Food and Drug Administration has approved generic versions of one of the country's top-selling drugs made by eight different companies, the agency said Thursday.

SILVER SPRING, Md. — The Food and Drug Administration has approved generic versions of one of the country's top-selling drugs made by eight different companies, the agency said Thursday.

May 15, 2012

Pfizer apparently is relenting on its attempt to drive sales of its top cholesterol drug as several new generic versions look set to enter the market, according to published reports.

NEW YORK — Pfizer apparently is relenting on its attempt to drive sales of its top cholesterol drug as several new generic versions look set to enter the market, according to published reports.

The Associated Press reported that Pfizer was "quietly" giving up on the drug Lipitor (atorvastatin) after an $87 million campaign to continue marketing the drug despite generic competition.

April 11, 2012

Move over, Lipitor: There's a new top drug on the market, according to published reports.

NEW YORK — Move over, Lipitor: There's a new top drug on the market, according to published reports.

April 9, 2012

Drug maker Pfizer is taking a marketing campaign for one of its drugs to Walgreens' Chicago flagship store to raise awareness about high cholesterol and healthy eating, the company said Monday.

CHICAGO — Drug maker Pfizer is taking a marketing campaign for one of its drugs to Walgreens' Chicago flagship store to raise awareness about high cholesterol and healthy eating, the company said Monday.

March 26, 2012

The recent Food and Drug Administration public meeting on driving future switch potential by way of the pharmacist and/or health technology sparked some discussion on what’s next.


The recent Food and Drug Administration public meeting on driving future switch potential by way of the pharmacist and/or health technology sparked some discussion on what’s next.


March 6, 2012

The Food and Drug Administration is asking for additional data before it approves a new cholesterol drug made by Merck, the drug maker said.

WHITEHOUSE STATION, N.J. — The Food and Drug Administration is asking for additional data before it approves a new cholesterol drug made by Merck, the drug maker said.

Merck said the agency issued a complete response letter for its regulatory approval application for a drug that would combine the cholesterol drug Zetia (ezetimibe) with atorvastatin, the active ingredient in Pfizer's Lipitor. A complete response letter means that the FDA cannot approve a drug application in its current form.

February 28, 2012

Drugs widely used to treat cholesterol may cause increases in blood sugar and other symptoms, the Food and Drug Administration said Tuesday.

SILVER SPRING, Md. — Drugs widely used to treat cholesterol may cause increases in blood sugar and other symptoms, the Food and Drug Administration said Tuesday.

February 17, 2012

The Food and Drug Administration has approved a drug made by Merck for Type 2 diabetes, the drug maker said. Merck announced the approval of Janumet XR (sitagliptin and metformin hydrochloride) extended-release tablets as a once-daily treatment for the disease.


SUPPLIER NEWS — The Food and Drug Administration has approved a drug made by Merck for Type 2 diabetes, the drug maker said. Merck announced the approval of Janumet XR (sitagliptin and metformin hydrochloride) extended-release tablets as a once-daily treatment for the disease.


February 15, 2012

Managed care and prescription plans are working to switch patients to generic versions of Pfizer's Lipitor despite the drug maker's efforts to reduce costs for the branded version, a new study suggested.

PHOENIX — Managed care and prescription plans are working to switch patients to generic versions of Pfizer's Lipitor despite the drug maker's efforts to reduce costs for the branded version, a new study suggested.

According to a report released Wednesday by Wolters Kluwer Pharma Solutions' inThought research group, while Lipitor (atorvastatin) has 41% of the market share of all dispensed prescriptions of atorvastatin, it has 35% of the payer approval volume.

February 3, 2012

For all the fears about the patent cliff, at least one disease state seems to be on the up-and-up in terms of new drug development and new products.

WHAT IT MEANS AND WHY IT'S IMPORTANT — For all the fears about the patent cliff, at least one disease state seems to be on the up-and-up in terms of new drug development and new products.

(THE NEWS: FDA approves Bydureon. For the full story, click here.)

February 2, 2012

The Food and Drug Administration has given tentative approval to a generic cholesterol drug made by Mylan, the drug maker said Thursday.

PITTSBURGH — The Food and Drug Administration has given tentative approval to a generic cholesterol drug made by Mylan, the drug maker said Thursday.

Mylan announced that it had received tentative approval for a generic version of Pfizer's Lipitor (atorvastatin calcium) in the 10-mg, 20-mg, 40-mg and 80-mg strengths.

February 1, 2012

For the past several years, drug industry experts have spoken in terms of the “patent cliff,” the period when the patents covering several blockbuster drugs are set to expire, thus leaving their manufacturers with a big, gaping hole in their revenues as those drugs face competition from generics.

For the past several years, drug industry experts have spoken in terms of the “patent cliff,” the period when the patents covering several blockbuster drugs are set to expire, thus leaving their manufacturers with a big, gaping hole in their revenues as those drugs face competition from generics.

January 20, 2012

One analysis report after another seems to confirm that the generic drug market is in for a huge shift as the number of blockbuster drugs losing patent protection is set to dwindle over the next several years. A recent report by Frost & Sullivan seems to confirm that sentiment.

WHAT IT MEANS AND WHY IT'S IMPORTANT — One analysis report after another seems to confirm that the generic drug market is in for a huge shift as the number of blockbuster drugs losing patent protection is set to dwindle over the next several years. A recent report by Frost & Sullivan seems to confirm that sentiment.

January 20, 2012

In the Feb. 7, 2011, issue, Drug Store News named three major issues that would define 2011 for the world of generic drugs. Those issues were drug safety, generic user fees and patent settlements.

In the Feb. 7, 2011, issue, Drug Store News named three major issues that would define 2011 for the world of generic drugs. Those issues were drug safety, generic user fees and patent settlements.

January 20, 2012

If the patent cliff were a sports team, Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin) would be its mascot.

If the patent cliff were a sports team, Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin) would be its mascot. Because it’s the top-selling drug, well, ever — with 2010 sales well in excess of $7 billion in the United States alone — Lipitor’s loss of patent protection on Nov. 30, 2011, didn’t start or end the patent cliff but in many ways symbolized it.


January 3, 2012

Pharmacy technology provider PDX is partnering with Mscripts to allow existing PDX Classic and Enterprise Pharmacy System customers to add mobile to their customer-facing offerings, the companies said.

SUPPLIER NEWS — Pharmacy technology provider PDX is partnering with Mscripts to allow existing PDX Classic and Enterprise Pharmacy System customers to add mobile to their customer-facing offerings, the companies said. The features will give pharmacies an outreach channel to improve their bin management and will-call services, as well as allow them to easily identify aging prescriptions and use the Mscripts mobile application to remind customers to pick up their prescriptions.


December 23, 2011

Drug makers will focus on patient-specific therapies instead of drugs designed for use by a broad range of people over the next decade, according to a new report released Thursday by Thomson Reuters.

PHILADELPHIA — Drug makers will focus on patient-specific therapies instead of drugs designed for use by a broad range of people over the next decade, according to a new report released Thursday by Thomson Reuters.

The report, titled "The Changing Role of Chemistry in Drug Discovery" and based on drug industry productivity, patent data and other dynamics and trends, was released in recognition of the International Year of Chemistry 2011.